Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health (NYSE: ELAN) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13-14, 2022. CFO Todd Young will be featured in a fireside chat on June 13 at 6:20 p.m. ET. Investors can access a live audio webcast via Elanco's investor website, with a replay available for 30 days.

Elanco Animal Health (NYSE: ELAN) will attend the Stifel 2022 Jaws and Paws Conference on June 1, 2022. CEO Jeff Simmons is scheduled to participate in a fireside chat at 3:00 p.m. ET. A live audio webcast of the event will be accessible on Elanco’s investor website, with a replay available for 30 days.

Elanco Animal Health reported Q1 2022 revenue of $1,225 million, a 1% decline year-over-year, but a 2% increase in constant currency. Net income stood at $48 million, up from a $61 million loss in Q1 2021. Adjusted EPS was $0.36, slightly down from $0.37. The company updated its full-year revenue guidance to a range of $4,700-$4,755 million, affected by foreign exchange rates. A strategic alliance with Royal DSM for Bovaer, a methane-reducing product, aims to generate significant future revenue. Despite some market pressures, Elanco remains confident in its growth strategy.

Elanco and Royal DSM have formed a strategic alliance to enhance sustainability in livestock farming by developing the methane-reducing product, Bovaer^®, in the U.S. Elanco gains exclusive rights to commercialize the product, which has the potential for over US$200 million in annual revenue in the U.S. alone, contributing to the Global Methane Pledge goal of a 30% emission reduction by 2030. Royal DSM will benefit from royalty income and increased production capacity, promoting a significant environmental impact through reduced methane emissions from cattle.

Elanco Animal Health Incorporated (NYSE: ELAN) is set to announce its first quarter 2022 financial results on May 9, 2022, at 8:00 a.m. eastern time. The announcement will be accompanied by a conference call for investors and media, providing insights into the company's performance. The details of the call will be accessible via a live webcast on Elanco’s website. As a global leader in animal health, Elanco focuses on innovating products and services to improve animal welfare and create value for various stakeholders.

Elanco Animal Health has announced plans for a new global headquarters in Indianapolis, featuring a 220,000 square foot structure. The campus aims to promote innovation and sustainability, incorporating environmentally-friendly materials and designs. The project will rejuvenate a long-idle site, expanding White River State Park and enhancing local connectivity. Elanco’s initiative is supported by strategic partnerships, including funding for new ventures. Construction is expected to take 2-3 years, influenced by incentive packages from the State and City.

Elanco Animal Health announced a successful tender offer for its 4.272% Senior Notes due 2023, with about $406.4 million (54.19% of total principal) tendered by the April 11, 2022 deadline. The company increased the tender cap from $250 million to $406.4 million. Validly tendered notes will receive a total consideration of $1,035 per $1,000 principal amount. The offer expires on April 25, 2022, and all conditions remain unchanged except for the tender cap increase.

Elanco Animal Health and Ginkgo Bioworks have launched BiomEdit, a new company focused on microbiome innovations for animal health. BiomEdit aims to develop probiotics and other solutions addressing urgent needs in livestock health, including antibiotic resistance. With an initial funding of $40 million, BiomEdit will operate independently, utilizing Elanco’s microbiome R&D expertise and intellectual property. This strategic separation allows Elanco to concentrate more effectively on its late-stage pet health pipeline while facilitating the growth of BiomEdit in the animal health sector.

Elanco Animal Health Incorporated (NYSE: ELAN) has initiated a cash tender offer for up to $250 million in aggregate principal amount of its 4.272% Senior Notes due 2023. The offer, detailed in the Offer to Purchase dated March 29, 2022, will expire at midnight New York City time on April 25, 2022. Holders who tender their notes by April 11, 2022, will be eligible for a total consideration of $1,035 per $1,000 principal amount. The offer is subject to certain conditions.